

“Immunotherapy Biomarkers in the Gynecologic Tract: MMR, PD-L1, and Beyond”

Anne M. Mills, MD

Associate Professor of Pathology
Anatomic & Clinical Pathology Residency Program Director
Gynecologic & Breast Pathology Fellowship Director
University of Virginia Department of Pathology



At the conclusion of this activity, the participant will be able to:

1. Explain the role of mismatch repair, microsatellite instability testing, and tumor mutational burden in identifying candidates for checkpoint inhibition.
2. Confidently interpret PD-L1 immunostaining as a biomarker for anti-PD-1 checkpoint inhibition in cervical carcinoma.
3. Understand potential biomarkers in the pipeline such as POLE mutation testing, neoantigen load, and immunohistochemistry for MHC class I, checkpoint molecules (such as TIM-3, LAG-3, and VISTA), and immune-inhibitory enzymes (such as IDO1).



In support of improving patient care, VCU Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Accreditation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Credit Designation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System designates this live activity for a maximum of **1.00 AMA PRA Category 1 Credit(s)**™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships:

The following planners, moderators or speakers have the following financial relationship(s) with commercial interests to disclose: Nothing to disclose